iMeta · 2024 · 17 citations · 8 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer Cell SignalingCancer ImmunotherapyImmunotherapy For Solid TumorsLiver CancerTumor Microenvironment ModulationLiver Tumor AblationLiver Tumor MicroenvironmentLiver Tumor TherapyPrognostic Marker AssessmentPrognostic Marker EvaluationTumor-associated Antigen Targeting
After RFA treatment in patients with liver cancer, the expression of SLC7A11/xCT and the proportion of DCs in the TME were significantly increased. SLC7A11/xCT is a poor prognostic marker for liver cancer and is mainly expressed in DCs in the TME. Targeting xCT in DCs combined with RFA significantly enhances anti-tumor immunity, suppressing tumor growth and offering a promising strategy for improved therapeutic outcomes in liver cancer.
8
A conserved dendritic-cell regulatory program limits antitumour immunity
Bárbara Maier, Andrew M. Leader, Steven T. Chen et al. · Nature · 2020 · 935 citations · Full text
Life Sciences, Immunology, Oncology +12
SLC7A11 expression level dictates differential responses to oxidative stress in cancer cells
Yuelong Yan, Hongqi Teng, Qinglei Hang et al. · Nature Communications · 2023 · 314 citations · Full text
Medicine, Cancer Biology, Oncology +17
PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses against Tumor
Liangrong Shi, Lujun Chen, Changping Wu et al. · Clinical Cancer Research · 2016 · 310 citations · Full text
Medicine, Immunology, Oncology +17